Key result
Novel oral anticoagulants offer convenience for VTE and atrial fibrillation, but their ability to reduce thrombosis or bleeding compared to optimally controlled warfarin is limited.
Population
Patients requiring thrombosis prophylaxis and long-term anticoagulation
Comparison
Novel oral anticoagulants vs Warfarin or parenteral alternatives
Design
Review
Authors
Loading...
May favor optimally controlled warfarin where feasible; leaves open net NOAC benefits amid variable real-world INR control.
Novel oral anticoagulants offer convenience and potential cost savings in certain settings compared to traditional therapies, though their clinical superiority over optimally controlled warfarin may be limited.
Rojas‐Hernandez et al. (2013) conducted a review in Venous thromboembolism and atrial fibrillation. Novel oral anticoagulants vs. Warfarin and parenteral alternatives was evaluated. Novel oral anticoagulants offer convenience for VTE and atrial fibrillation, but their ability to reduce thrombosis or bleeding compared to optimally controlled warfarin is limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: